INT113516

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.51
First Reported 2000
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 16
Total Number 16
Disease Relevance 8.37
Pain Relevance 5.32

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Fas) aging (Fas) extracellular region (Fas)
plasma membrane (Fas) nucleus (Fas) cytoplasm (Fas)
Anatomy Link Frequency
fat 2
joint 1
Fas (Rattus norvegicus)
Pain Link Frequency Relevance Heat
agonist 15 99.96 Very High Very High Very High
Kinase C 1 99.72 Very High Very High Very High
rheumatoid arthritis 48 99.40 Very High Very High Very High
opiate 15 99.26 Very High Very High Very High
antagonist 10 98.86 Very High Very High Very High
fortral 12 98.50 Very High Very High Very High
cytokine 7 94.64 High High
dexamethasone 43 89.72 High High
Morphine 14 88.64 High High
withdrawal 25 84.80 Quite High
Disease Link Frequency Relevance Heat
Apoptosis 413 100.00 Very High Very High Very High
Repression 5 100.00 Very High Very High Very High
Death 61 99.52 Very High Very High Very High
Rheumatoid Arthritis 48 99.40 Very High Very High Very High
Lymphoproliferative Disease 3 99.36 Very High Very High Very High
Obesity 90 97.88 Very High Very High Very High
Disease 104 96.44 Very High Very High Very High
Cancer 25 93.24 High High
Synovitis 3 92.24 High High
Opiate Addiction 13 85.36 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Similarly, the selective sigma(1) agonist (+)-SKF 10047 also decreased native Fas (37%) and the effect was blocked by the sigma(1) antagonist BD 1063.
Negative_regulation (decreased) of Fas associated with antagonist and agonist
1) Confidence 0.51 Published 2003 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 14530904 Disease Relevance 0.29 Pain Relevance 1.40
In the liver and adipose tissue of several genes involved in fat metabolism and mobilization that we measured, only fatty acid synthase (FAS) was significantly down-regulated by celecoxib treatment.
Negative_regulation (down-regulated) of FAS in fat associated with obesity
2) Confidence 0.50 Published 2007 Journal Exp. Biol. Med. (Maywood) Section Abstract Doc Link 17463161 Disease Relevance 0.26 Pain Relevance 0.14
There were no differences in the level of prostaglandin E(2) in these tissues, indicating that celecoxib decreases fat accumulation by down-regulating FAS through a COX-2-independent mechanism.
Negative_regulation (down-regulating) of FAS in fat
3) Confidence 0.44 Published 2007 Journal Exp. Biol. Med. (Maywood) Section Abstract Doc Link 17463161 Disease Relevance 0.24 Pain Relevance 0.13
Chronic pentazocine (10-80 mg/kg, 5 days), a mixed opiate drug and sigma(1) receptor agonist, decreased native (48%) and glycosylated (38-82%) Fas proteins.
Negative_regulation (decreased) of Fas associated with fortral, agonist and opiate
4) Confidence 0.43 Published 2003 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 14530904 Disease Relevance 0.39 Pain Relevance 1.42
This might be mediated by inhibition of the Fas ligand pathway.
Negative_regulation (inhibition) of Fas
5) Confidence 0.38 Published 2009 Journal Anesthesiology Section Body Doc Link 19934868 Disease Relevance 0 Pain Relevance 0
Similarly, the selective sigma(1) agonist (+)-SKF 10047 also decreased native Fas (37%) and the effect was blocked by the sigma(1) antagonist BD 1063.
Negative_regulation (decreased) of Fas associated with antagonist and agonist
6) Confidence 0.37 Published 2003 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 14530904 Disease Relevance 0.29 Pain Relevance 1.40
Four additional hemi-palindromic sequences, identical to half a canonical ERE are dispersed throughout intron#1, and may also contribute to estrogen repression of Fas.
Negative_regulation (repression) of Fas associated with repression
7) Confidence 0.34 Published 2004 Journal BMC Neurosci Section Body Doc Link PMC395829 Disease Relevance 0.17 Pain Relevance 0
Surprisingly (see discussion), concurrent exposure to the estrogenic antagonist 4-hydroxytamoxifen did not prevent the estrogen-induced reduction in Fas.


Negative_regulation (reduction) of Fas associated with antagonist
8) Confidence 0.29 Published 2004 Journal BMC Neurosci Section Body Doc Link PMC395829 Disease Relevance 0.27 Pain Relevance 0.09
In line with the above mentioned changes, PVAT fatty acyl lipid composition showed significant changes in FRD rats, mainly an increase in saturated FAs and a decrease in mono- and polyunsaturated FAs, resulting in a rise of the saturated/MUFA and saturated/PUFA ratios.
Negative_regulation (decrease) of FAs associated with obesity
9) Confidence 0.22 Published 2010 Journal Cardiovasc Diabetol Section Body Doc Link PMC2974659 Disease Relevance 0.80 Pain Relevance 0.03
Hence there was an up-regulation of pathways such as nfkb, rela, tnfr2 and tob1 while there was a down-regulation of FAS.
Negative_regulation (regulation) of FAS
10) Confidence 0.21 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2607546 Disease Relevance 0.06 Pain Relevance 0.08
The observation that mice with the

lymphoproliferative or generalized lymphoproliferative disorder, which have mutations that inactivate Fas and Fas ligand, respectively, develop pathology similar to that observed in immune-mediated diseases [9,10] illustrates that reduced apoptosis may play an important role in the pathogenesis of synovitis.

Negative_regulation (inactivate) of Fas associated with synovitis, apoptosis, disease and lymphoproliferative disease
11) Confidence 0.18 Published 2000 Journal Arthritis Res Section Body Doc Link PMC17810 Disease Relevance 1.16 Pain Relevance 0.10
B

activation [14,15,16], a relative deficiency of functional Fas ligand in the RA joint [17], and expression of antiapoptotic molecules, such as bcl-2 [3] and sentrin [18].

Negative_regulation (deficiency) of Fas in joint associated with rheumatoid arthritis
12) Confidence 0.17 Published 2000 Journal Arthritis Res Section Body Doc Link PMC17810 Disease Relevance 1.40 Pain Relevance 0.19
In comparison with model group 2, Bcl-2 IR-positive cell number of model group 1 decreased significantly (P < 0.05), Bax, Fas and FasL IR-positive cell number and Bax/Bcl-2 of model group 1 were significantly higher (P < 0.01, fl. 05).
Negative_regulation (decreased) of Fas
13) Confidence 0.14 Published 2008 Journal Zhen Ci Yan Jiu Section Body Doc Link 18928115 Disease Relevance 0.05 Pain Relevance 0
We assessed the transcriptional profiles of seven anti-apoptotic proteins (Bcl-2, Bcl-XL, inhibitors of apoptosis protein-1 (IAP-1), IAP-2, X-linked IAP (XIAP), Fas-associated death-domain-like IL-1?
Negative_regulation (inhibitors) of Fas associated with apoptosis and death
14) Confidence 0.09 Published 2007 Journal The Journal of Endocrinology Section Abstract Doc Link PMC2173947 Disease Relevance 1.14 Pain Relevance 0.16
The observation that mice with the

lymphoproliferative or generalized lymphoproliferative disorder, which have mutations that inactivate Fas and Fas ligand, respectively, develop pathology similar to that observed in immune-mediated diseases [9,10] illustrates that reduced apoptosis may play an important role in the pathogenesis of synovitis.

Negative_regulation (inactivate) of Fas associated with synovitis, apoptosis, disease and lymphoproliferative disease
15) Confidence 0.08 Published 2000 Journal Arthritis Res Section Body Doc Link PMC17810 Disease Relevance 1.16 Pain Relevance 0.10
This normally causes inhibition of the ubiquitin-proteosome complex and release of proapoptotic factors.36 Direct binding of the propargylamine moiety, however, prevents downstream activation of proapoptotic factors,37–40 partially via activation of anti-apoptotic factors including Bcl-2 and protein kinase C, and also by downregulation of proapoptotic catalysts including FAS and Bax protein families.36
Negative_regulation (downregulation) of FAS associated with kinase c and apoptosis
16) Confidence 0.07 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2695242 Disease Relevance 0.69 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox